Technology areas: Communications • Transportation, E-Commerce & Mechanical Systems
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Chang Gung Memorial Hospital Linkou maintains a patent portfolio focused on Communications, currently managing 3 pending office actions. These actions are distributed across 3 distinct examiners, indicating that each pending matter is assigned to a different person. This distribution requires the company to navigate different examiner styles even within a small number of active cases.
The portfolio spans 2 distinct art units, which suggests that the Communications technology being pursued involves diverse technical classifications. GOEBEL, EMMA ROSE is identified as the busiest examiner for the company, and she is responsible for 1 busiest examiner pending action. This indicates that no single examiner holds a majority of the workload, as the 3 pending office actions are spread among the 3 distinct examiners.
For practitioners, the presence of 2 distinct art units means that prosecution strategies may need to be tailored to different internal USPTO policies. While the total volume of active cases is low, the lack of examiner overlap means each case requires an independent approach. Managing the workload of GOEBEL, EMMA ROSE and the 1 busiest examiner pending action ensures that the portfolio's progress is not dependent on a single individual.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (33%) |
| §101 + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOEBEL, EMMA ROSE | 1 | 52.2% | +33.5% |
| HAIDER, SYED | 1 | 83.4% | +7.0% |
| WHALEY, PABLO S | 1 | 25.1% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936606 | METHOD FOR ANALYZING AORTIC COMPUTED TOMOGRAPHY IMAGES AND SYSTEM IMPLEMENTING THE SAME | GOEBEL, EMMA ROSE | — |
| 18742623 | METHOD OF CELL-CLUSTER ANALYSIS | HAIDER, SYED | — |
| 17728224 | METHOD AND KIT FOR EVALUATING PROGNOSIS IN PATIENT WITH BREAST CANCER | WHALEY, PABLO S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18936606 | METHOD FOR ANALYZING AORTIC COMPUTED TOMOGRAPHY IMAGES AND SYSTEM IMPLEMENTING THE SAME | GOEBEL, EMMA ROSE | — |
| 17728224 | METHOD AND KIT FOR EVALUATING PROGNOSIS IN PATIENT WITH BREAST CANCER | WHALEY, PABLO S | — |
| Art Unit | Apps |
|---|---|
| 2633 | 1 |
| 3619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18936606 | METHOD FOR ANALYZING AORTIC COMPUTED TOMOGRAPHY IMAGES AND SYSTEM IMPLEMENTING THE SAME | GOEBEL, EMMA ROSE | — | §101§102§103 | Non-Final OA | — | Pending | Nov 04, 2024 |
| 18742623 | METHOD OF CELL-CLUSTER ANALYSIS | HAIDER, SYED | 2633 | §101 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 17728224 | METHOD AND KIT FOR EVALUATING PROGNOSIS IN PATIENT WITH BREAST CANCER | WHALEY, PABLO S | 3619 | §101§102§112 | Non-Final OA | — | Pending | Apr 25, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial